Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Yogic Eye Exercises for Computer Vision Syndrome in Female Design Students

13 de septiembre de 2026 actualizado por: Nada Aldahlawi, King Saud University

Effect of a Four-Week Yogic Eye Exercise Program on Computer Vision Syndrome Symptoms in Female University Students: A Single-Arm Pre-Post Study

Computer vision syndrome (CVS) is a cluster of eye and musculoskeletal complaints - dryness, redness, blurred vision, foreign body sensation, excessive tearing, and neck, shoulder or back pain - that arises from prolonged work at a digital display. It is common among university students, and optical, pharmacological and nutritional treatments have given inconsistent results. Yoga-based eye exercises have been proposed as a brief, inexpensive alternative that requires no equipment.

This study tested whether a short, structured programme of yogic eye exercises reduces self-reported CVS symptoms in female undergraduates in a graphic design and digital media programme, a group whose coursework demands sustained, colour-critical near work at a screen.

All 36 female students enrolled in the programme took part. Each attended one supervised training session and then performed a 13-minute sequence of relaxation exercises (slow blinking, gazing at a distant target, acupressure around the eyes) and strengthening exercises (eye rolling, nose-tip gazing) three days a week for four weeks, a total of 12 sessions, reporting completion of each session on the same day.

Nine symptoms - five ocular and four musculoskeletal - were rated on a four-point scale (never, rarely, sometimes, always) at the start and again at the end of week 4. The main question was whether the average of all nine ratings fell over the four weeks. Every participant served as her own comparison; there was no control group and no masking.

Descripción general del estudio

Descripción detallada

Design. Single-arm, pre-post interventional study in which each participant served as her own control, conducted in the Graphic Design and Digital Media programme of Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. No control group was recruited and no masking was applied.

Participants. All 36 female students enrolled in the programme were invited and all agreed, so the convenience sample was a complete enumeration of the eligible cohort. The programme admits female students only. All participants were in the 18-22 year age band.

Intervention. Participants were trained in a single supervised group session before baseline and given written and illustrated instructions. Each session comprised relaxation exercises (slow blinking; gazing at a fine detail of a distant target; acupressure massage of periocular points) followed by strengthening exercises (eye-rolling movements; nose-tip gazing, in which the participant focuses on the extended thumb, moves it slowly toward the nose tip, holds for five seconds and moves it away). The combined sequence took approximately 13 minutes and was performed three days per week for four consecutive weeks, giving 12 sessions in total. After the training session participants practised independently and reported completion of each session the same day in a monitored group thread, so adherence was verified session by session rather than recalled at the end.

Assessment. Symptoms were assessed with an adapted electronic questionnaire administered at baseline and at the end of week 4. The instrument was developed by reviewing validated instruments in the literature, refining items with subject-matter experts and pilot testing in six female students. It recorded demographic details, medical history relevant to ocular surface dryness, habitual computer use, and nine symptom items each rated on a 4-point Likert scale (1 = never, 2 = rarely, 3 = sometimes, 4 = always). The identical instrument and platform were used at both time points.

Analysis. The primary outcome, the total symptom score, and the two domain scores were compared with the paired-samples t-test, with the Wilcoxon signed-rank test reported alongside where normality was not supported; item-level differences were tested with the Wilcoxon signed-rank test. Because nine item-level comparisons were made, p-values were adjusted by the Holm-Bonferroni procedure. No data were imputed and no subgroup or interaction analyses were performed. No formal a priori sample size calculation was performed; the study enrolled the entire eligible cohort.

Registration. This record was created retrospectively. The study was investigator-initiated and approved by the Princess Nourah bint Abdulrahman University Institutional Review Board on 20 December 2020, before the first participant was enrolled on 15 March 2021. The design, intervention and outcome measures recorded here are those specified in the approved protocol and are unchanged.

Tipo de estudio

Intervencionista

Inscripción (Actual)

36

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Riyadh, Arabia Saudita, 11671
        • : Princess Nourah bint Abdulrahman University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Female undergraduate enrolled in the Graphic Design and Digital Media programme at Princess Nourah bint Abdulrahman University
  • Use of a computer for at least one month before the study
  • Able to read and understand English
  • Provided written informed consent

Exclusion Criteria:

  • Diagnosis of Sjögren syndrome
  • Diagnosis of keratoconjunctivitis sicca
  • Use of medications known to reduce tear production, for example antihistamines
  • Use of isotretinoin

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Yogic eye exercise programme
All participants received the same intervention: a 13-minute session of yogic relaxation and strengthening eye exercises, performed three days per week for four consecutive weeks (12 sessions).

A 13-minute sequence performed three days per week for four consecutive weeks (12 sessions in total).

Relaxation component: slow blinking; gazing at a fine detail of a distant target; acupressure massage of periocular points.

Strengthening component: eye-rolling movements; nose-tip gazing (focus on the extended thumb, move it slowly toward the nose tip, hold five seconds, move away; repeat twice, approximately 25 seconds per cycle).

Delivery: one supervised group training session before baseline, written and illustrated instructions, then independent home practice with same-day reporting of each completed session in a monitored group thread.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in total symptom score at week 4
Periodo de tiempo: Baseline and week 4
Arithmetic mean of all nine self-reported symptom items - five ocular (eye dryness, red eye, foreign body sensation, blurred vision, excessive tearing) and four musculoskeletal (shoulder pain, back pain, loss of sensation in the fingers, loss of sensation in the hands) - each rated on a 4-point Likert scale (1 = never, 2 = rarely, 3 = sometimes, 4 = always). The total score ranges from 1 to 4; lower scores indicate fewer symptoms. Collected by self-completed electronic questionnaire.
Baseline and week 4

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in ocular symptom domain score at week 4
Periodo de tiempo: Baseline and week 4
Mean of five self-reported ocular symptom items - eye dryness, red eye, foreign body sensation, blurred vision and excessive tearing - each rated on a 4-point Likert scale (1 = never to 4 = always). The domain score ranges from 1 to 4; lower scores indicate fewer symptoms.
Baseline and week 4
Change from baseline in muscular symptom domain score at week 4
Periodo de tiempo: Baseline and week 4
Mean of four self-reported musculoskeletal symptom items - shoulder pain, back pain, loss of sensation in the fingers and loss of sensation in the hands - each rated on a 4-point Likert scale (1 = never to 4 = always). The domain score ranges from 1 to 4; lower scores indicate fewer symptoms.
Baseline and week 4
Change from baseline in each individual symptom item at week 4
Periodo de tiempo: Baseline and week 4
Each of the nine symptom items analysed separately: eye dryness, red eye, foreign body sensation, blurred vision, excessive tearing, shoulder pain, back pain, loss of sensation in the fingers, loss of sensation in the hands. Each is rated on a 4-point Likert scale (1 = never to 4 = always); lower scores indicate fewer symptoms.
Baseline and week 4

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Baseline screen-use behaviour
Periodo de tiempo: Baseline
Descriptive characterisation of daily computer use (<2, 2-4, 4-6, >6 hours), daily screen viewing in darkness (same bands), and whether computer use was continuous or interrupted by breaks.
Baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de marzo de 2021

Finalización primaria (Actual)

16 de abril de 2021

Finalización del estudio (Actual)

16 de abril de 2021

Fechas de registro del estudio

Enviado por primera vez

7 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

7 de septiembre de 2026

Publicado por primera vez (Actual)

11 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The de-identified participant-level dataset and the analysis code that support the findings are held by the corresponding author.

Marco de tiempo para compartir IPD

Available on request from the date of publication, indefinitely.

Criterios de acceso compartido de IPD

Requests should be directed to the corresponding author and will be considered on reasonable scientific grounds.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir